UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003957
Receipt number R000004766
Scientific Title Evaluation of the efficacy of Sitagliptin plus peginterferon alfa 2b /ribavirin combination therapy in CHC patients with insulin resistance
Date of disclosure of the study information 2010/08/01
Last modified on 2020/03/31 17:42:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the efficacy of Sitagliptin plus peginterferon alfa 2b /ribavirin combination therapy in CHC patients with insulin resistance

Acronym

ESPRIT study

Scientific Title

Evaluation of the efficacy of Sitagliptin plus peginterferon alfa 2b /ribavirin combination therapy in CHC patients with insulin resistance

Scientific Title:Acronym

ESPRIT study

Region

Japan


Condition

Condition

Hepatitis C

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of Sitagliptin and PEG/RBV combination therapy on insulin resistance and the antiviral effect

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

SVR rate

Key secondary outcomes

HOMA-IR decrease
safet


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Dietary intervention(3 months before PEG/RIB treatment)

Interventions/Control_2

Dietary intervention(3 months before PEG/RIB treatment) + sitagliptin 50mg Q.D.oral administration) from 3 month before PEG/RIB treatment to end of PEG/RIB treatment)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

chronic hepatitis C
Insulin resistance(HOMA≥2)
HCV viral load≥ 5 log copies/mL
HCV genotype 1

Key exclusion criteria

1) Pregnant , possibly pregnant or lactating women
2) Patients with severe heart diseases
3) Chronic kidney failure or creatinine clearance of <=50 mL/min
4) Current or history of severe psychiatric disorder
5) Autoimmune hepatitis
6) Intolerance to sitagliptin
7) medication for diabetes

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shuhei Nishiguchi

Organization

Hyogo College Of Medicine

Division name

Division of Hepatobiliary and Pancreatic Diseases Department of Internal Medicine

Zip code


Address

1-1 Mukogawa, Nishinomiya, Hyogo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Masaki Saito

Organization

Hyogo College Of Medicine

Division name

Division of Hepatobiliary and Pancreatic Diseases Department of Internal Medicine

Zip code


Address

1-1 Mukogawa, Nishinomiya, Hyogo, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

Hyogo College Of Medicine

Institute

Department

Personal name



Funding Source

Organization

Hyogo College Of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

兵庫医科大学病院(兵庫県)


Other administrative information

Date of disclosure of the study information

2010 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2010 Year 05 Month 13 Day

Date of IRB

2010 Year 06 Month 04 Day

Anticipated trial start date

2010 Year 08 Month 01 Day

Last follow-up date

2014 Year 05 Month 01 Day

Date of closure to data entry

2014 Year 08 Month 01 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 07 Month 27 Day

Last modified on

2020 Year 03 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004766


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name